9th Annual Biomarkers Congress
25 Feb 2014 - 26 Feb 2014 - Manchester, UK
The Biomarkers Congress will cover the latest advances in biomarker discovery and verification, including multiplex platforms, nanotechnology platforms and multiple reaction monitoring. Our expert speakers will also discuss efforts to increase biomarker sensitivity and specificity through genomic analysis, systems biology approaches and better sample management. In the Companion Diagnostics stream, presentations will cover Rx/Dx co-development, methods to increase predictive significance and regulatory considerations.
To build on the clinical case studies shared at last year’s event, we are pleased to introduce the co-located ‘Biomarkers in Clinical Development Congress’, focusing on the role of biomarkers in clinical decision making, drug efficacy prediction and clinical safety. Key decision makers in personalised medicine will complement these discussions with their insights into adaptive trial design, patient stratification and markers for improved treatment response.
The increasing interest in biomarker discovery in recent years has pushed biomarker research into the foreground of the modern pharmaceutical industry. New identification technologies have both widened the scope of biomarker research and underlined the need for robust validation, improved predictive value and the clear demonstration of clinical relevance.
Contact Danielle Dalby to download the agenda and for attendance information on firstname.lastname@example.org or call +44 (0)1865 248455